Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25333

Title:	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Authors:	Dalgleish, Angus G Stebbing, Justin Adamson, Douglas Ja Arif, Seema Safia Bidoli, Paolo Chang, David Cheeseman, Sue Diaz-Beveridge, Robert Fernandez-Martos, Carlos Glynne-Jones, Rob Granetto, Cristina Massuti, Bartomeu McAdam, Karen McDermott, Raymond Martín, Andrés J Muñoz Papamichael, Demetris Pazo-Cid, Roberto Vieitez, Jose M Zaniboni, Alberto Carroll, Kevin J Wagle, Shama Gaya, Andrew Mudan, Satvinder S View more
Mesh:	Aged Aged, 80 and over Antimetabolites, Antineoplastic Biomarkers, Tumor Cancer Vaccines Carcinoma, Pancreatic Ductal Combined Modality Therapy Deoxycytidine Disease-Free Survival Europe Female Humans Kaplan-Meier Estimate Male Middle Aged Neoplasm Metastasis Pancreatic Neoplasms Treatment Outcome Immunotherapy, Active View more
Issue Date:	2016
Citation:	Br. J. Cancer.2016 09;(115)7:789-96
Abstract:	Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma.
PMID:	27599039
URI:	https://hdl.handle.net/20.500.12530/25333
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC5046215.pdf		424.4 kB	Adobe PDF	View/Open